Allogeneic Gamma-Delta T Cell Therapies – Advancing Clinical Data in Phase 1 & Navigating the Path to Solid Tumor Applications

Time: 10:00 am
day: Day One


  • Overview of Gamma-delta T cells and their advantages in the Allogeneic setting
  • Update on Allogeneic INB-100 clinical program, evaluating the safety, efficacy and patient response using gamma-delta T cells for Leukemia
  • How to move beyond Leukemias and into solid tumors using Allogeneic Gamma-Delta T cell therapies, how to think about safety, durability and response